Key facts
- Biocellis’s last known valuation is $5.3M (Jun 2025).
- It has raised $1.3M; the latest was Accelerator/Incubator ($120K) in Dec 2025.
- Notable investors include General Inception, The Institut Pasteur, Diana (England).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Biocellis
- ·The full record, as it builds
Funding rounds
No funding rounds for Biocellis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biocellis
Developer of biological reagents and devices designed for in vitro research and diagnostics. The company offers bioluminescence and immunoassays that combine ultra-sensitivity and focus on products encompassing a range of biological reagents and diagnostic devices designed to support scientific investigation and medical diagnosis, enabling research institutions and diagnostic laboratories to increase their understanding of biological processes and enhance disease detection and monitoring capabilities.
- Sector
- Healthcare
- HQ
- La Tronche, France
- Founded
- 2024
- Website
- biocellis.com/
- Ownership
- Privately Held (backing)
Biocellis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biocellis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biocellis in its N-PORT filings yet. We sweep new filings monthly.